# GSK

When Compute Meets Patients: How AI Is Rewiring Drug Discovery—and China and the US Are Betting Different Chips

AI is transforming drug discovery from an expensive exercise in trial-and-error into a data- and compute-driven engineering problem. The result is a pragmatic partnership between American algorithmic and compute strength and China’s unrivalled clinical scale, producing record licensing deals even as regulatory and scientific bottlenecks persist.